Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 2009

View Archived Issues

Novel beta-secretase 1 inhibitors developed by Schering-Plough for AD therapy

Potent dual orexin receptor antagonist SB-649868 shows hypnotic properties in multiple studies

Novartis reports trial results of adjuvanted cell culture-based influenza A(H1N1) vaccine

Autologous immunosuppressive regulatory B cells show promise in autoimmune disease therapy in vivo

DTriP-22 shows potent anti-enterovirus 71 activity by inhibiting NS5B

Andrographolide analogue exhibits significant antibacterial activity

FDA Advisory Committee recommends approval of romidepsin for cutaneous T-cell lymphoma

Takeda presents results from first quarter of 2009, ending June 30

OSI initiates two clinical trials of OSI-906

GSK claims AMPA glutamate receptor ligands for psychotic disorders

FDA grants Cytopia clearance for CYT-387 trials in U.S.

Enanta identifies novel hepatitis C virus NS3 NS4A protease inhibitors

Phase II study suggests telmisartan may reverse epirubicin cardiotoxicity in cancer patients

Sanwa describes thyroid hormone receptor ligands for the treatment of hyperlipidemia

Taiho presents retinoid RARalpha receptor agonists as antitumor agents

Grifols launches anti-hepatitis B immunoglobulin, Niuliva

Endo launches Valstar for bladder cancer

Takeda receives FDA complete response letter for fixed-dose Actos and alogliptin benzoate

FDA accepts for review Bristol-Myers Squibb's BLA for belatacept

FDA issues warning for Myfortic

Array BioPharma reports topline results from phase II ARRY-162 trial

Dilafor reports phase II tafoxiparin results in preventing protracted labor

Acura and King Pharmaceuticals provide update on Acurox NDA

Shionogi reports results from first quarter 2009, ended June 30

Japanese launch for GSK's dutasteride for benign prostatic hyperplasia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.